Oberland Capital


Oberland Capital is a private investment firm dedicated to funding innovation in the global healthcare industry. With approximately $3.2 billion in assets under management, the firm specializes in flexible investment structures tailored to meet the specific needs of its partners. Oberland Capital offers a broad range of creative financing solutions, including the monetization of royalty streams, acquisition of future product revenues, project-based financing structures, and investments in traditional debt and equity. The firm is committed to accelerating the development and commercialization of promising healthcare products to create value for its partners and transform patient care.

Oberland Capital

Oberland Capital


What We Do

Oberland Capital provides flexible, long-term investment structures that meet the specific strategic and financial objectives of its partners.

The firm has substantial transactional experience across the globe, enabling it to deploy innovative structures tailored to the specifics of each geography.

Oberland Capital combines scientific, operational, and financial expertise to design creative capital solutions for the life sciences sector.

The firm provides significant amounts of capital, ranging from $50 million to over $300 million, to accelerate growth opportunities.


Fund Size

Geographic Focus

Industry Focus

Investment Range


Portfolio

Verastem Oncology announced a debt refinancing with Oberland Capital and a strategic commercialization partnership with IQVIA.

#Biotechnology

BillionToOne secured $140 million in non-dilutive financing with Oberland Capital to strengthen its balance sheet and secure its path to profitability and IPO.

#Molecular Diagnostics

Centessa Pharmaceuticals entered into a $300 million financing agreement with Oberland Capital to advance development programs and pursue strategic business development opportunities.

#Pharmaceuticals

Axogen announced a new seven-year financing agreement with Oberland Capital to support sales and marketing growth strategies.

#Medical Technology

Curis sold a portion of Erivedge royalties to Oberland Capital for up to $135.7 million.

#Biotechnology

Esperion and Oberland Capital announced a $200 million funding agreement for the development of bempedoic acid and the bempedoic acid/ezetimibe combination tablet.

#Pharmaceuticals

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.